Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

NEW YORK, Aug. 27, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

http://www.reportlinker.com/p0922673/Endpoints---Clinical-Trials-in-Respiratory-Diseases---Pulmonary-Function-Tests-Biomarkers-and-Quality-of-Life-Questionnaires-All-Play-Prominent-Roles.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

Summary Scope Summary

- This report deals with different types of endpoint used in respiratory clinical trials. It contains brief account of advantages, disadvantages and regulatory aspects of each type of endpoint.

- This report provides in-depth analysis of clinical trial endpoints used in asthma, COPD, cystic fibrosis and PAH clinical trials.

- This report covers complete account of primary and secondary endpoints used in Phase III and Phase II clinical trials in above mentioned respiratory diseases.

- In this report characterization and segmentation of trials based on their status, along with specific use of endpoints is also provided.

- This report provides profiling of major marketed drugs based on their safety, efficacy and clinical study details.

- The report contains company profiling of major companies associated with marketing of major respiratory drugs covering asthma, COPD, cystic fibrosis and PAH.

- This report also includes endpoint analysis of terminated trials for asthma, COPD, cystic fibrosis and PAH. Analysis of terminated trials can be used in designing more robust trials and avoid any issues, which can result in termination of trial.

Reasons to buy

- To analyze the major primary and secondary endpoint used in disease specific clinical trials.

- Reinforce R&D strategies by identifying new endpoints to be used in disease and clinical phase specific clinical trials. This can increase positive outcome from a trial and aid in bringing molecules with increased efficiency and better safety profiles.

- Develop key strategic initiatives by understanding the key focus of major companies developing drugs in respiratory franchise.

- Build effective strategies by clinical phase wise endpoint analysis of clinical trials. This can help in reducing the drug's time to market.

- Exploit strategies for designing of clinical trials by identifying the advantages and disadvantages involved with the use of specific endpoints.

1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 102 Introduction 133 Clinical Trials Endpoints in Respiratory Diseases - An Overview 143.1 Introduction 143.2 Types of Endpoints 143.2.1 Primary Endpoints 143.2.2 Secondary Endpoints 143.2.3 Surrogate Endpoints 154 Endpoints - Clinical Trials in Asthma - Marketed and Pipeline Products Assessment 164.1 Introduction 164.2 Primary Endpoints Used in Asthma Clinical Trials 204.2.1 Pulmonary Function Tests: 204.2.2 Vital Signs and Physical Activity 204.2.3 Biomarkers 204.2.4 Serious Adverse Events 204.3 Secondary Endpoints Used in Asthma Clinical Trials 214.3.1 Pharmacokinetics and Pharmacodynamics 214.3.2 Quality of Life Scores 214.3.3 Clinical Laboratory Tests – Biochemistry and Serum Hematology 214.3.4 Use of Rescue Medication 214.4 Asthma Therapeutics – Major Marketed Drugs 214.4.1 Singulair (Montekeulast Sodium) 214.4.2 Accolate Accoleit, Vanticon (Zafirlukast) 224.4.3 Zyflo (Zileuton) 234.4.4 Foradil (Formoterol Fumarate Inhalation Powder) 244.4.5 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 254.4.6 Xolair (Omalizumab) 274.4.7 Serevent Diskus (Salmaterol Xinafoate Inhalation Powder) 284.4.8 Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) 294.5 Asthma Therapeutics – Promising Drugs under Clinical Development 304.5.1 Daxas (Roflumilast) (Daxas, APTA 2217, B9302-107, BY 217, BYK 20869) 304.6 Phase III Clinical Trial Analysis 314.6.1 Completed Trial Analysis 314.6.2 Active Trial Analysis 354.6.3 Terminated Trial Analysis 394.7 Phase II Clinical Trial Analysis 414.7.1 Completed Trial Analysis 414.7.2 Active Trial Analysis 454.7.3 Terminated Trial Analysis 495 Endpoints - Clinical Trials in Chronic Obstructive Pulmonary Disorder - Marketed and Pipeline Products Assessment 765.1 Introduction 765.2 Primary Endpoints Used in COPD Clinical Trials 805.2.1 Pulmonary Function Tests 805.2.2 Baseline Dyspnea Index and Borg-Dyspnea Score 805.2.3 Rate of Exacerbations 805.2.4 Induced Sputum Analysis 805.2.5 Biomarkers of COPD 805.3 Secondary Endpoints Used in COPD Clinical Trials 805.3.1 Exercise Endurance Time 805.3.2 Serum Hematology 805.3.3 Six Minute Walk Distance 805.3.4 Time to First Exacerbation 815.4 COPD Therapeutics – Major Marketed Drugs 815.4.1 Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) 815.4.2 Brovana (Arformoterol) 825.4.3 Foradil Aerolizer (Formoterol Fumarate Inhalation Powder) 835.4.4 Symbicort (Budesonide/Formoterol Fumarate Dihydrate) 845.4.5 Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) 855.4.6 Daxas (roflumilast) 875.5 COPD Therapeutics – Promising Drugs Under Clinical Development 885.5.1 Aclidinium Bromide 885.5.2 NVA237 (Glycopyrronium Bromide) 895.5.3 Dulera 895.6 Phase III Clinical Trial Analysis 905.6.1 Completed Trial Analysis 905.6.2 Active Trials Analysis 945.6.3 Terminated Trial Analysis 985.7 Phase II Clinical Trial Analysis 1005.7.1 Completed Trial Analysis 1005.7.2 Active Trial Analysis 1045.7.3 Terminated Trial Analysis 1076 Endpoints - Clinical Trials in Cystic Fibrosis - Marketed and Pipeline Products Assessment 1256.1 Introduction 1256.2 Primary Endpoints Used in Cystic Fibrosis Clinical Trials 1296.2.1 Coefficient of Fat Absorption 1296.2.2 Lung Microbiology 1296.2.3 Biomarkers 1296.3 Secondary Endpoints Used in Cystic Fibrosis Clinical Trials 1296.3.1 Nasal Potential Difference 1296.3.2 Sweat Chloride Concentration 1296.4 Cystic Fibrosis Therapeutics – Major Marketed Drugs 1296.4.1 Tobi (Tobramycin Inhalation Solution) 1296.4.2 Pulmozyme (Dornase Alfa) 1306.4.3 Cayston (aztreonam for Inhalation Solution) 1316.4.4 Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M) 1326.5 Cystic Fibrosis – Promising Drugs Under Clinical Development 1336.5.1 Denufosol Tetrasodium Inhalation Solution (INS37217) 1336.5.2 VX-770 1346.5.3 Bronchitol 1346.5.4 Ataluren (PTC-124) 1356.6 Phase III – Clinical Trial Analysis 1366.6.1 Completed Trial Analysis 1366.6.2 Active Trial Analysis 1386.6.3 Terminated Trial Analysis 1416.7 Phase II – Clinical Trial Analysis 1436.7.1 Completed Trial Analysis 1436.7.2 Active Trial Analysis 1466.7.3 Terminated Trial Analysis 1497 Endpoints - Clinical Trials in Pulmonary Arterial Hypertension - Marketed and Pipeline Products Assessment 1567.1 Introduction 1567.1.1 Classification of Pulmonary Hypertension 1567.2 Primary Endpoints Used in Pulmonary Hypertension Trials 1617.2.1 Cardiopulmonary Hemodynamic Test 1617.2.2 Six Minutes Walking Distance 1617.2.3 Biomarkers 1617.3 Secondary Endpoints Used in Pulmonary Hypertension Trials 1617.3.1 Time to Clinical Worsening 1617.3.2 SF-36 Health Survey 1617.4 Pulmonary Arterial Hypertension – Major Marketed Drugs 1617.4.1 Tracleer 1617.4.2 Remodulin 1627.4.3 Revatio 1637.4.4 Ventavis 1647.4.5 Letairis 1657.4.6 Adcirca 1667.5 Pulmonary Arterial Hypertension – Promising Drugs under Clinical Development 1677.5.1 ACT-064992 1677.5.2 Oral Treprostinil 1687.5.3 ACT-293987 1687.5.4 Riociguat (BAY63-2521) 1697.6 Phase III Clinical Trial Analysis 1707.6.1 Completed Trial Analysis 1707.6.2 Active Trial Analysis 1727.6.3 Terminated Trial Analysis 1757.7 Phase II Clinical Trial Analysis 1777.7.1 Completed Trial Analysis 1777.7.2 Active Trial Analysis 1807.7.3 Terminated Trial Analysis 1838 Endpoints - Clinical Trials in Respiratory Diseases - Company Profiling 1878.1 GlaxoSmithKline Plc 1878.1.1 Overview 1878.1.2 Respiratory Disease Portfolio 1878.2 AstraZeneca 1888.2.1 Overview 1888.2.2 Respiratory Disease Portfolio 1888.3 F.Hoffmann La Roche 1888.3.1 Overview 1888.3.2 Respiratory Disease Portfolio 1888.4 Merck & Co Inc 1898.4.1 Overview 1898.4.2 Respiratory Disease Portfolio 1898.5 Novartis AG 1898.5.1 Overview 1898.5.2 Respiratory Disease Portfolio 1908.6 Boehringer Ingelheim GmbH 1908.6.1 Overview 1908.6.2 Respiratory Disease Portfolio 1909 Clinical Trials Endpoints in Respiratory Therapeutics - Appendix 1919.1 Market Definitions 1919.2 Abbreviations 1919.3 Sources 1929.4 Research Methodology 1929.4.1 Clinical Trial Design Overview 1929.4.2 Top Four Indications in Respiratory Therapy Area and their Product Profiling 1939.4.3 Marketed and Pipeline Products Assessment 1939.4.4 Company Profiling 1939.4.5 Expert Panel Validation 1949.5 Contact Us 1949.6 Disclaimer 194

1.1 List of Tables

Table 1: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Distribution of Clinical Trials, By Company, 2000-2010 19Table 2: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 32Table 3: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 34Table 4: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 36Table 5: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 38Table 6: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 39Table 7: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 40Table 8: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 42Table 9: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 44Table 10: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 46Table 11: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 48Table 12: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 49Table 13: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 51Table 14: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Phase III Clinical Trials, 2000-2010 52Table 15: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Phase II Clinical Trials, 2000-2010 64Table 16: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Distribution of Clinical Trials, By Company, 2000-2010 79Table 17: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 91Table 18: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 93Table 19: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 95Table 20: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 97Table 21: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 98Table 22: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 99Table 23: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 101Table 24: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 103Table 25: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 104Table 26: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 106Table 27: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 107Table 28: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 108Table 29: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Phase III Clinical Trials, 2000-2010 109Table 30: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Phase II Clinical Trials, 2000-2010 117Table 31: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Distribution of Clinical Trials, By Company, 2000-2010 128Table 32: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 136Table 33: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 137Table 34: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 139Table 35: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 140Table 36: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 141Table 37: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 142Table 38: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 144Table 39: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 145Table 40: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 147Table 41: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 148Table 42: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 149Table 43: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 150Table 44: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase III Clinical Trials, 2000-2010 151Table 45: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase II Clinical Trials, 2000-2010 153Table 46: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Distribution of Clinical Trials, By Company, 2002-2010 160Table 47: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2002-2010 170Table 48: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2002-2010 171Table 49: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2002-2010 172Table 50: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2002-2010 174Table 51: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2002-2010 175Table 52: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2002-2010 176Table 53: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2002-2010 177Table 54: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2002-2010 179Table 55: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2002-2010 180Table 56: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2002-2010 182Table 57: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2002-2010 183Table 58: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2002-2010 184Table 59: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase III Clinical Trials, 2002-2010 185Table 60: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase II Clinical Trials, 2002-2010 186Table 61: GlaxoSmithKline Plc, Marketed Respiratory Drugs Portfolio, 2010 187Table 62: AstraZeneca, Marketed Respiratory Drugs Portfolio, 2010 188Table 63: F.Hoffmann La Roche, Marketed Respiratory Drugs Portfolio, 2010 188Table 64: Merck & Co, Marketed Respiratory Drugs Portfolio, 2010 189Table 65: Novartis AG, Marketed Respiratory Drugs Portfolio, 2010 190Table 66: Boehringer Ingelheim, Marketed Respiratory Drugs Portfolio, 2010 190

1.2 List of Figures

Figure 1: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Total Number Of Clinical Trials, 2000-2010 16Figure 2: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Phase of Clinical Trials, 2000-2010 17Figure 3: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Status of Clinical Trials, 2000-2010 18Figure 4: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Distribution of Clinical Trials, By Company (%), 2000-2010 19Figure 5: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 31Figure 6: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 33Figure 7: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 35Figure 8: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 37Figure 9: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 39Figure 10: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 40Figure 11: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 41Figure 12: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 43Figure 13: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 45Figure 14: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 47Figure 15: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 49Figure 16: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 50Figure 17: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Total Number of Clinical Trials, 2000-2010 76Figure 18: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Phase of Clinical Trials, 2000-2010 77Figure 19: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Status of Clinical Trials, 2000-2010 78Figure 20: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Distribution of Clinical Trials, By Company (%), 2000-2010 79Figure 21: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 90Figure 22: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 92Figure 23: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 94Figure 24: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 96Figure 25: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 98Figure 26: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 99Figure 27: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 100Figure 28: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 102Figure 29: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 104Figure 30: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 105Figure 31: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 107Figure 32: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 108Figure 33: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Total Number of Clinical Trials, 2000-2010 125Figure 34: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase of Clinical Trials, 2000-2010 126Figure 35: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Status of Clinical Trials, 2000-2010 127Figure 36: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Distribution of Clinical Trials, By Company (%), 2000-2010 128Figure 37: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 136Figure 38: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 137Figure 39: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 138Figure 40: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 139Figure 41: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 141Figure 42: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 142Figure 43: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 143Figure 44: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 145Figure 45: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 146Figure 46: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 148Figure 47: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 149Figure 48: Endpoints – Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 150Figure 49: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Total Number of Clinical Trials, 2002-2010 157Figure 50: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase of Clinical Trials, 2002-2010 158Figure 51: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Status of Clinical Trials, 2002-2010 159Figure 52: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Distribution of Clinical Trials, By Company (%),2002-2010 160Figure 53: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2002-2010 170Figure 54: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2002-2010 171Figure 55: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2002-2010 172Figure 56: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2002-2010 173Figure 57: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2002-2010 175Figure 58: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%),2002-2010 176Figure 59: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2002-2010 177Figure 60: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2002-2010 178Figure 61: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2002-2010 180Figure 62: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2002-2010 181Figure 63: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2002-2010 183Figure 64: Endpoints – Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2002-2010 184

Companies mentioned

GlaxoSmithKline Plc

AstraZeneca

F.Hoffmann La Roche

Merck & Co Inc

Novartis AG

Boehringer Ingelheim GmbH

To order this report:Drug Discovery and Development Industry: Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent RolesMore  Market Research ReportCheck our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker